全部照片(1)

重要文件

來源證明/COA

檢視所有文件

SML2308

硫酸阿扎那韦硫酸酯

Name: 硫酸阿扎那韦 硫酸酯
Brand: SIGMA

≥95% (HPLC)

同義詞:

(3S,8S,9S,12S)-1,14-Dimethyl-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate sulfate

登入查看組織和合約定價

全部照片(1)

About This Item

經驗公式（希爾表示法）:

C₃₈H₅₂N₆O₇ · H₂SO₄

CAS號碼:

229975-97-7

分子量：:

802.93

分類程式碼代碼:

12352200

NACRES:

NA.77

暫時無法取得訂價和供貨情況

推薦產品

Slide 1 of 10

1 of 10

Sigma-Aldrich

SML1796

阿扎那韦

Sigma-Aldrich

SML3051

Emtricitabine

Sigma-Aldrich

L1295

拉米夫定

Sigma-Aldrich

SML0491

利托那韦

Sigma-Aldrich

I0383

异丁酰基辅酶 A 锂盐

Sigma-Aldrich

F3680

10058-F4

Sigma-Aldrich

I4883

布洛芬

Sigma-Aldrich

M1323

Midostaurin hydrate

Sigma-Aldrich

SML3387

Rilpivirine

Supelco

PHR3002

硫酸阿扎那韦硫酸酯

化驗

≥95% (HPLC)

形狀

powder

光學活性

[α]/D -40 to -50°, c = 1 in methanol: water (1:1)

儲存條件

desiccated

顏色

white to beige

溶解度

H₂O: 2 mg/mL, clear

運輸包裝

wet ice

儲存溫度

2-8°C

SMILES 字串

O[C@@H](CN(CC1=CC=C(C2=CC=CC=N2)C=C1)NC([C@@H](NC(OC)=O)C(C)(C)C)=O)[C@@H](NC([C@@H](NC(OC)=O)C(C)(C)C)=O)CC3=CC=CC=C3.O=S(O)OO

InChI

1S/C38H52N6O7.H2O4S/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28;1-5(2,3)4/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47);(H2,1,2,3,4)/t29-,30-,31+,32+;/m0./s1

InChI 密鑰

DQSGVVGOPRWTKI-QVFAWCHISA-N

尋找類似的產品？前往產品比較指南

生化／生理作用

Antiviral HIV Protease Inhibitor

Atazanavir sulfate is the prodrug of Atazanavir, an antiviral HIV protease inhibitor.

象形圖

GHS08,GHS05

訊號詞

Danger

危險聲明

H318,H372

防範說明

P260 - P264 - P270 - P280 - P305 + P351 + P338 - P314

危險分類

Eye Dam. 1 - STOT RE 1

標靶器官

Heart,Liver

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.

Lisa Rosenblatt et al.

BMC infectious diseases, 16, 492-492 (2016-09-20)

A previous cohort study indicated that atazanavir (ATV), a protease inhibitor used for HIV treatment, is not associated with an increased risk of cardiovascular (CV) events. The objective of this study was to compare the risk of CV events among

Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?

Vincent Calvez et al.

The Journal of antimicrobial chemotherapy, 72(1), 19-28 (2016-09-23)

For many patients living with HIV-1, the efficacy of combined ART (cART) has made the infection turn to a chronic disease. Because cART is associated with a risk of long-term toxicity, switching patients with virological success to another therapy remains

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).

Jose R Castillo-Mancilla et al.

The Journal of antimicrobial chemotherapy, 71(6), 1609-1618 (2016-02-20)

The multinational PEARLS (ACTG A5175) study, conducted mainly in resource-limited settings, identified an increased treatment failure rate among HIV-infected individuals randomized to once-daily unboosted atazanavir, didanosine-EC, and emtricitabine compared with efavirenz-based regimens. We evaluated associations between selected human genetic polymorphisms

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務

重要文件

硫酸阿扎那韦硫酸酯